文献速递病毒性肝炎

注射吸毒者丙肝治愈后再感染率及危险因素

Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs.
PubMed 文献 · Clin Infect Dis · 2021-01-01

基于SIMPLIFY和D3FEAT两项临床试验,纳入177例近期注射吸毒或接受阿片受体激动剂治疗的丙肝治愈者,中位随访1.8年。总再感染率为3.1/100人年,报告针具共用者高达17.9/100人年。年轻年龄和针具共用与再感染相关,提示需持续监测和预防策略。

要点

  • 丙肝治愈后注射吸毒者总体再感染率为3.1/100人年。
  • 报告针具共用者再感染率升至17.9/100人年。
  • 年轻年龄和针具共用是再感染的危险因素。

核心结论

  • 注射吸毒者丙肝治愈后再感染率为3.1/100人年,针具共用者高达17.9/100人年。
  • 年轻年龄和针具共用与再感染相关,需持续监测和预防策略以实现丙肝消除。

研究设计与样本

  • 基于SIMPLIFY和D3FEAT两项临床试验,纳入2016年3月至2017年2月在8个国家入组的近期注射吸毒或接受OAT的丙肝治愈者。
  • 共177例有再感染风险者,中位年龄48岁,73%男性,73%报告持续注射吸毒。
  • 总随访风险时间254人年,中位随访1.8年(范围0.2-2.8年),再感染经病毒测序确认。

主要发现

  • 确认8例再感染,总再感染率3.1/100人年(95%CI 1.6-6.3)。
  • 报告针具共用者再感染率17.9/100人年(95%CI 5.8-55.6)。
  • 年轻年龄和针具共用与HCV再感染相关。

临床怎么用

  • 对持续注射吸毒的丙肝治愈者应持续监测再感染。
  • 针对针具共用者需强化减害和预防策略以降低再感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this analysis was to calculate the incidence of hepatitis C virus (HCV) reinfection and associated factors among 2 clinical trials of HCV direct-acting antiviral treatment in people with recent injecting drug use or currently receiving opioid agonist therapy (OAT). METHODS: Participants who achieved an end-of-treatment response in 2 clinical trials of people with recent injecting drug use or currently receiving OAT (SIMPLIFY and D3FEAT) enrolled between March 2016 and February 2017 in 8 countries were assessed for HCV reinfection, confirmed by viral sequencing. Incidence was calculated using person-time of observation and associated factors were assessed using Cox proportional hazard models. RESULTS: Seventy-three percent of the population at risk of reinfection (n = 177; median age, 48 years; 73% male) reported ongoing injecting drug use. Total follow-up time at risk was 254 person-years (median, 1.8 years; range, 0.2-2.8 years). Eight cases of reinfection were confirmed for an incidence of 3.1/100 person-years (95% confidence interval [CI], 1.6-6.3) overall and 17.9/100 person-years (95% CI, 5.8-55.6) among those who reported sharing needles/syringes. Younger age and needle/syringe sharing were associated with HCV reinfection. CONCLUSIONS: These data demonstrate the need for ongoing monitoring and improved strategies to prevent HCV reinfection following successful treatment among people with ongoing injecting drug use to achieve HCV elimination. CLINICAL TRIALS REGISTRATION: NCT02336139 and NCT02498015.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cunningham EB, Hajarizadeh B, Amin J, et al. Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. Clin Infect Dis. 2021. PMID: 32166305. doi:10.1093/cid/ciaa253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。